Abstract: The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

Abstract: A front body of a vehicle includes left and right front side members extending forward from a left end part and a right end part of a lower end of a dash panel, an upper back beam connecting front ends of the front side members and extending in a width direction of the vehicle, left and right front center members extending forward from a central left part and a central right part of the lower end of the dash panel, a lower back beam connecting front ends of the front center members and extending in the width direction of the vehicle, and first and second support members, the first support member connecting the left front side member and the left front center member and the second support member connecting the right front side member and the right front center member.

Abstract: The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

Abstract: The present disclosure relates to an onshore lithium-recovering device for a lithium ion adsorption and desorption process including a supply unit for supplying lithium-containing water in which lithium is dissolved, a composite unit, a washing unit, a desorbing liquid unit, an extract liquid unit, a pressure adjusting unit, a discharge unit, and a control unit. Therefore, the lithium adsorption means is moved onshore so it is possible to significantly reduce the plant installation cost and the operating cost as compared to the lithium recovery process that operates the conventional offshore plant.

Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.

Abstract: The present disclosure relates to an onshore lithium-recovering device for a lithium ion adsorption and desorption process including a supply unit for supplying lithium-containing water in which lithium is dissolved, a composite unit, a washing unit, a desorbing liquid unit, an extract liquid unit, a pressure adjusting unit, a discharge unit, and a control unit. Therefore, the lithium adsorption means is moved onshore so it is possible to significantly reduce the plant installation cost and the operating cost as compared to the lithium recovery process that operates the conventional offshore plant.

Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present invention relates to a composition for inhibiting and preventing myopathy having a bean leaf extract as an active ingredient. The composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present specification relates to a composition for preventing, alleviating or treating burnout syndrome, containing a natural extract as an active ingredient. According to one aspect of the present invention, the composition contains a ginseng fruit extract, and thus is useful for preventing, treating and alleviating burnout syndrome. In addition, according to one aspect of the present invention, the composition further contains ginseng fruit and one or more selected from the group consisting of red ginseng, Angelica gigas, Cornus officinalis, Cervi parvum corni, and Nigella sativa, so as to maximize the synergistic effect among two or more ingredients, thereby exhibiting excellent effects on the prevention, treatment and alleviation of burnout syndrome. Therefore, there is an advantage of making individuals and society mentally and physically healthy since burnout syndrome can be prevented, treated and alleviated, by using the composition of the present invention.

Abstract: The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.

Abstract: The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: A method for screening an EMT inhibitor including: contacting EPRS, Snail1 protein, and a test agent; and measuring a change in a binding level between the EPRS and the Snail1 protein.

Abstract: The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced.